Astellas Pharma Inc. today announced that the Center for Drug Evaluation of the China National Medical Products Administration (NMPA) has accepted the Biologics License Application

Ionis Pharmaceuticals, Inc. today announced it has expanded its existing collaboration with AstraZeneca to include exclusive rights for AstraZeneca to commercialize eplontersen in Latin

Biosion USA, Inc. a global clinical-stage R&D biotechnology company, today announced the phase 2 study initiation for the evaluation of BSI-045B, an anti-TLSP mAb, in the treatment of atopic dermatitis.

Today, the U.S. Food and Drug Administration approved RiVive, 3 milligram (mg) naloxone hydrochloride nasal spray for over-the-counter (OTC), nonprescription use for the emergency treatment of known or suspected opioid overdose.

KORU Medical Systems, Inc., a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions, today announced an agreement with a biopharmaceutical company to validate

WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced the successful GMP release of its CHO cell-based drug substance (DS) manufacturing facility located in Suzhou

Bio-Rad Laboratories, Inc. and QIAGEN N.V., today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating

Everest Medicines, a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, announced today XERAVA

Clinical stage Australian biotech company HaemaLogiX Ltd is pleased to announce it has entered into a co-development agreement with the world leading Peter MacCallum Cancer Centre

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received approval to conduct